Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Takara Bio Inc. ( (JP:4974) ) has issued an update.
Takara Bio Inc. announced its decision to merge with its wholly owned subsidiary, ViSpot, Inc., effective May 1, 2025. The merger aims to streamline management and boost business expansion, with Takara Bio remaining as the surviving entity. ViSpot, which specializes in viral safety testing services, was previously in a state of insolvency, but this issue was resolved prior to the merger. The merger is expected to have a minor impact on Takara Bio’s consolidated business performance.
More about Takara Bio Inc.
Takara Bio Inc. operates in the biotechnology industry, specializing in the manufacturing and sales of reagents and instruments, contract development and manufacturing organization (CDMO) services, and gene therapy business. The company is focused on expanding its market presence through strategic mergers and acquisitions.
YTD Price Performance: -17.43%
Average Trading Volume: 317,187
Technical Sentiment Signal: Buy
Current Market Cap: Yen104.4B
For an in-depth examination of 4974 stock, go to TipRanks’ Stock Analysis page.